Chengyue Wu

Assistant Professor


Curriculum vitae



Imaging Physics

The University of Texas MD Anderson Cancer Center



Abstract PD9-07: The rate of parenchymal enhancement during DCE-MRI reflects response to neoadjuvant therapy


Journal article


John Virostko, E. Higgins, Chengyue Wu, A. Sorace, D. Patt, B. Goodgame, T. Yankeelov
2020

Semantic Scholar DOI
Cite

Cite

APA   Click to copy
Virostko, J., Higgins, E., Wu, C., Sorace, A., Patt, D., Goodgame, B., & Yankeelov, T. (2020). Abstract PD9-07: The rate of parenchymal enhancement during DCE-MRI reflects response to neoadjuvant therapy.


Chicago/Turabian   Click to copy
Virostko, John, E. Higgins, Chengyue Wu, A. Sorace, D. Patt, B. Goodgame, and T. Yankeelov. “Abstract PD9-07: The Rate of Parenchymal Enhancement during DCE-MRI Reflects Response to Neoadjuvant Therapy” (2020).


MLA   Click to copy
Virostko, John, et al. Abstract PD9-07: The Rate of Parenchymal Enhancement during DCE-MRI Reflects Response to Neoadjuvant Therapy. 2020.


BibTeX   Click to copy

@article{john2020a,
  title = {Abstract PD9-07: The rate of parenchymal enhancement during DCE-MRI reflects response to neoadjuvant therapy},
  year = {2020},
  author = {Virostko, John and Higgins, E. and Wu, Chengyue and Sorace, A. and Patt, D. and Goodgame, B. and Yankeelov, T.}
}

Abstract

Background: Dynamic contrast-enhanced MRI (DCE-MRI) plays a crucial role in breast cancer detection and monitoring of therapeutic response by assessing the tumor vascular network. The MRI contrast agent enhances not only tumor tissue, but also normal breast tissue, a phenomena known as background parenchymal enhancement (BPE). The degree of BPE can be variable between different individuals, is influenced by the hormonal milieu, and displays variable anatomical and kinetic patterns. Changes in BPE intensity over the course of neoadjuvant therapy (NAT) have been found to correlate with response to therapy in both the ipsilateral and contralateral breast. The present study assesses changes in the rate of BPE over the course of NAT to predict eventual response to NAT. Importantly, this study was conducted in collaboration with community-care centers (i.e., not research-oriented medical centers). Methods: Women with locally advanced breast cancer (N = 19) were imaged four times during the course of NAT: 1) prior to the start of NAT, 2) after 1 cycle of NAT, 3) after 2-4 cycles of NAT, and 4) 1 cycle after MRI #3. Imaging data was acquired on 3T Siemens Skyra scanners equipped with a 8- or 16-channel breast coils. Gadolinium-based contrast agent (0.1 mmol/kg of Multihance or 10 mL of Gadovist) was administered intravenously at 2 mL/sec after the acquisition of baseline scans. DCE-MRI data was collected in 10 sagittal slices with a temporal resolution of 7.27 sec for a total acquisition time of eight minutes. The tumor was semi-automatically segmented using a manually drawn region of interest (ROI) followed by fuzzy c-means clustering of a post-contrast high-resolution anatomical scan. Fibroglandular parenchyma was segmented from adipose tissue using fuzzy c-means clustering and further segmented into three concentric rings at prescribed radial distances from the tumor boundary. Enhancement time courses were temporally smoothed using a moving average filter of width 5 and normalized to baseline intensity to yield relative enhancement time courses. The enhancement slope, defined as the slope of the curve at half maximal intensity, was calculated from the kinetic uptake curve for the tumor, adipose, and concentric rings of fibroglandular tissue surrounding the tumor. Results: Prior to commencing NAT, women with faster tumoral enhancement had faster fibroglandular enhancement (r = 0.62, p Citation Format: John Virostko, Erin M Higgins, Chengyue Wu, Anna G Sorace, Debra Patt, Boone Goodgame, Thomas E Yankeelov. The rate of parenchymal enhancement during DCE-MRI reflects response to neoadjuvant therapy [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD9-07.


Share



Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in